Bulk Pharmaceutical API Sources for DEFERIPRONE

Bulk Pharmaceutical API Sources for DEFERIPRONE

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		379409_ALDRICH
TCI (Tokyo Chemical Industry)		H0944
Molport		MolPort-001-792-505
TimTec		ST093416
Amadis Chemical		A820470

Deferiprone Bulk API Supply Chain Analysis

Last updated: February 19, 2026

This report details the global supply landscape for deferiprone bulk active pharmaceutical ingredient (API), focusing on key manufacturers, production capacities, and regulatory standing. The analysis targets stakeholders involved in the procurement, manufacturing, and investment within the iron chelator market.

Who Are the Primary Bulk API Manufacturers for Deferiprone?

The global supply of deferiprone bulk API is concentrated among a limited number of manufacturers. These entities operate under stringent quality controls and often hold multiple regulatory certifications to serve diverse markets. Key players include:

• Apeloa Pharmaceutical Co., Ltd.

  • Location: China
  • Certifications: FDA inspected, CEP (Certificate of Suitability to the monographs of the European Pharmacopoeia)
  • Products: Deferiprone API, Deferiprone Film-Coated Tablets.
  • Notes: Apeloa is a significant producer of APIs and finished dosage forms, indicating integrated manufacturing capabilities. [1]

• Zydus Lifesciences Limited (formerly Cadila Healthcare)

  • Location: India
  • Certifications: US FDA, EU GMP (Good Manufacturing Practice), WHO GMP.
  • Products: Deferiprone API.
  • Notes: Zydus is a major Indian pharmaceutical company with a broad API portfolio and established global distribution. [2]

• Sigma-Aldrich (Merck KGaA)

  • Location: Global presence, with significant API manufacturing facilities.
  • Certifications: ISO 9001, relevant GMP certifications depending on facility and product.
  • Products: Deferiprone (laboratory and bulk quantities).
  • Notes: Sigma-Aldrich provides a range of chemicals and APIs for research and commercial use. Its role often involves supplying smaller quantities or for specific market segments. [3]

• Chiron Pharma (India) Pvt. Ltd.

  • Location: India
  • Certifications: WHO GMP.
  • Products: Deferiprone API.
  • Notes: A dedicated API manufacturer with a focus on specific therapeutic areas.

• Granada Biosciences

  • Location: India
  • Certifications: cGMP compliant.
  • Products: Deferiprone API.
  • Notes: Focuses on the production of APIs for various pharmaceutical applications.

What is the Production Capacity and Market Share of Key Manufacturers?

Specific production capacities for deferiprone API are not publicly disclosed by individual manufacturers. However, market share can be inferred based on regulatory approvals, export volumes, and reported sales of related finished dosage forms.

• China and India are the dominant regions for bulk API production, including deferiprone. Manufacturers in these countries benefit from lower manufacturing costs and established supply chain infrastructure.
• Apeloa Pharmaceutical and Zydus Lifesciences are considered significant contributors to the global supply, given their extensive regulatory approvals and broad product portfolios extending to finished formulations.
• The market for deferiprone API is not as large as for blockbuster drugs, meaning production is often scaled to meet specific demand rather than operating at maximum theoretical capacity. Manufacturers may reallocate capacity to other APIs based on market dynamics.

What are the Regulatory Requirements for Deferiprone API Manufacturing?

Manufacturing of deferiprone API must comply with international pharmaceutical standards to ensure product quality, safety, and efficacy. Key regulatory considerations include:

• Good Manufacturing Practice (GMP): Compliance with current GMP guidelines (cGMP) as set by regulatory bodies such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO). This encompasses facility design, equipment, personnel training, process validation, and quality control. [4]
• Drug Master Files (DMFs): Manufacturers typically file DMFs with regulatory agencies. A DMF is a submission to a regulatory agency that contains detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more drugs. This allows drug product manufacturers to reference the information in their marketing applications without having to disclose proprietary details.
• Certificate of Suitability (CEP): Issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM), a CEP certifies that the API complies with the requirements of the relevant monograph in the European Pharmacopoeia. This simplifies the regulatory process for obtaining marketing authorization in European countries. [5]
• Pharmacopoeial Standards: Deferiprone API must meet the specifications outlined in major pharmacopoeias, including the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). These standards define identity, purity, assay, and other critical quality attributes. [6]
• Impurity Profiling: Rigorous control and monitoring of process-related impurities and degradation products are essential. Regulatory agencies require detailed impurity profiles and validated analytical methods for their detection and quantification.

What is the Current Status of Deferiprone Patent Expirations?

The patent landscape for deferiprone itself has largely expired. Deferiprone, chemically known as 1,2-dimethyl-3-hydroxypyridin-4-one, has been available for many years.

• Original Patents: The foundational patents covering the composition of matter and early uses of deferiprone have expired. For instance, patents filed in the late 1980s and early 1990s have long since lapsed. [7]
• Newer Patents: While the core compound is off-patent, there may still be patents related to:
  • Formulations: Novel drug delivery systems, extended-release formulations, or combination therapies.
  • Manufacturing Processes: Innovative or more efficient synthesis routes that may offer improved purity or yield.
  • New Indications: Patents covering the use of deferiprone for treating conditions other than its primary approved uses (e.g., specific types of anemia, neurodegenerative diseases with iron dysregulation).
• Generic Competition: The expiration of primary patents has enabled the entry of generic manufacturers of deferiprone API and finished dosage forms. This has led to increased competition and potential price reductions.

What Are the Key Quality Control and Analytical Standards for Deferiprone API?

Ensuring the quality of deferiprone API is paramount. Manufacturers adhere to strict analytical standards throughout the production process.

• Identification:
  • Infrared (IR) Spectroscopy: To confirm the molecular identity.
  • High-Performance Liquid Chromatography (HPLC): Retention time comparison with a reference standard.
• Assay:
  • HPLC is the primary method for quantitative determination of deferiprone content, typically requiring a purity of 98.0% to 102.0% on an anhydrous basis.
• Purity:
  • Related Substances (HPLC): Quantifies known and unknown impurities. Limits are set for individual impurities and total impurities. For example, the Ph. Eur. monograph specifies limits for specific related substances. [6]
  • Residual Solvents (Gas Chromatography, GC): Controls levels of solvents used during synthesis, adhering to ICH (International Council for Harmonisation) Q3C guidelines.
  • Heavy Metals: Limits for potentially toxic metal contaminants.
  • Water Content (Karl Fischer titration): To ensure appropriate moisture levels.
  • Sulphated Ash (Residue on Ignition): Measures the amount of inorganic impurities.
• Physical Properties:
  • Appearance: Typically a white to off-white crystalline powder.
  • Solubility: Deferiprone is soluble in water.
  • Melting Point: A characteristic range for crystalline solids.
• Microbiological Purity:
  • Total Aerobic Microbial Count (TAMC) and Total Yeast and Mold Count (TYMC): Limits are set to ensure the absence of excessive microbial contamination, especially for non-sterile APIs.
  • Absence of Specified Microorganisms: Testing for the absence of objectionable pathogens like E. coli or Salmonella.

What are the Future Market Trends and Potential Opportunities in Deferiprone API Supply?

The deferiprone API market is influenced by the prevalence of conditions requiring iron chelation therapy and advancements in drug development.

• Increasing Demand for Chronic Treatments: Diseases like thalassemia and myelodysplastic syndromes, which require lifelong iron chelation, are driving sustained demand. The growing global population and improved diagnostic capabilities contribute to this trend.
• Emerging Indications: Research into deferiprone's efficacy in other conditions, such as neurodegenerative diseases (e.g., Friedreich's ataxia, Parkinson's disease) where iron dysregulation plays a role, could open new market segments. Clinical trials exploring these applications are ongoing. [8]
• Supply Chain Resilience: Recent global events have highlighted the importance of robust and diversified API supply chains. Companies may seek to reduce reliance on single geographical sources, creating opportunities for manufacturers in regions outside traditional hubs or for those with strong business continuity plans.
• Quality and Compliance as Differentiators: As regulatory scrutiny intensifies, manufacturers with superior quality systems, advanced impurity control, and a proven track record of regulatory compliance will have a competitive advantage.
• Technological Advancements in Manufacturing: Adoption of continuous manufacturing or advanced process analytical technology (PAT) could lead to more efficient, cost-effective, and higher-quality API production.

Key Takeaways

The supply of deferiprone bulk API is primarily based in China and India, with manufacturers like Apeloa Pharmaceutical and Zydus Lifesciences being significant players. Adherence to stringent GMP standards, pharmacopoeial requirements, and regulatory filings (DMFs, CEPs) is critical for market access. The core composition-of-matter patents for deferiprone have expired, leading to generic competition. Future growth will be driven by the steady demand for chronic iron chelation therapies, potential expansion into new indications, and the strategic advantage of diversified and compliant supply chains.

FAQs

1. Are there any active patents that would prevent the generic manufacturing of deferiprone API? No, the primary patents covering the deferiprone compound have expired. However, patents on specific manufacturing processes or novel formulations may exist and require careful review.

2. Which regulatory agencies have approved the manufacturing facilities for leading deferiprone API suppliers? Leading suppliers, such as Apeloa Pharmaceutical and Zydus Lifesciences, have facilities inspected and approved by the US FDA, EMA (via national competent authorities and EDQM for CEPs), and WHO.

3. What are the typical specifications for deferiprone API purity? Deferiprone API typically requires a purity of 98.0% to 102.0% on an anhydrous basis, with stringent limits on individual and total related substances, residual solvents, and heavy metals as per major pharmacopoeias like USP and Ph. Eur.

4. Can deferiprone API be sourced from manufacturers in Europe or North America, or is it exclusively produced in Asia? While the majority of bulk API production, including deferiprone, is concentrated in Asia due to cost efficiencies, specialized suppliers or contract manufacturing organizations (CMOs) in Europe and North America may offer deferiprone API, particularly for niche markets or specific quality requirements.

5. What is the impact of ongoing clinical trials for new deferiprone indications on API demand? Positive outcomes from clinical trials exploring new indications could lead to increased long-term demand for deferiprone API, provided these indications receive regulatory approval. This could also spur investment in expanding production capacity or developing specialized API grades.

---

[1] Apeloa Pharmaceutical Co., Ltd. (n.d.). Product List. Retrieved from [Manufacturer's Official Website] [2] Zydus Lifesciences Limited. (n.d.). API Portfolio. Retrieved from [Manufacturer's Official Website] [3] Merck KGaA. (n.d.). Sigma-Aldrich Deferiprone. Retrieved from [Supplier's Official Website] [4] U.S. Food & Drug Administration. (n.d.). Current Good Manufacturing Practice (cGMP). Retrieved from [FDA Website] [5] European Directorate for the Quality of Medicines & HealthCare (EDQM). (n.d.). Certificates of Suitability (CEP). Retrieved from [EDQM Website] [6] United States Pharmacopeia. (n.d.). Deferiprone Monograph. (Subscription required). [7] European Pharmacopoeia. (n.d.). Deferiprone Monograph. (Subscription required). [8] National Institutes of Health. (n.d.). ClinicalTrials.gov. Retrieved from [ClinicalTrials.gov Website]